Effect of delta-aminolevulinic acid on protoporphyrin IX accumulation in tumor cells transfected with plasmids containing porphobilinogen deaminase DNA.
Recently, we reported that the delta-aminolevulinic acid (delta-ALA)-induced increase in porphobilinogen deaminase (PBGD) activity was closely correlated with an increase in the accumulation of protoporphyrin IX (PPIX), resulting in augmented phototoxicity. In this report, we asked whether increasing the cellular expression of PBGD by use of gene transfection techniques in vitro would further enhance delta-ALA-induced PPIX accumulation and hence, phototoxicity. For these experiments we constructed plasmid vectors containing the PBGD-DNA, using a reverse transcription-polymerase chain reaction-generated cDNA fragment encoded from its published sequence. Subsequently, transfection of the human mammary tumor cell line, MCF-7, and the human mesothelioma cell line, H-MESO-1, with the PBGD-DNA-containing plasmids was shown to produce a 2.5-2.7-fold increase in enzyme activity. Twenty-four hours after completion of the transfection procedure, transfectants were exposed for 3 h to 0.5 mM delta-ALA. Exposure of either wild type or transfectants to delta-ALA led to measurable levels of PPIX. Although this produced a modest but significant increase in intracellular PPIX content in H-MESO-1 cells compared to wild-type cells incubated with delta-ALA alone, the increase above the transfection control did not reach statistical significance. Likewise, a significant increase in PPIX was not observed in transfected MCF-7 cells subsequently exposed to delta-ALA. These data demonstrate that transient transfection of cells with the cDNA of PBGD was successful in elevating enzyme activity in both tumor cell lines, but this did not result in a comparable difference in the levels of PPIX. Such an approach for the study of other enzymes in the heme pathway should provide a model to better define rate-limiting steps in the delta-ALA induction of PPIX, and ultimately, to enhance the effectiveness of photodynamic therapy.
Hilf
R
R
Department of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, NY, USA. Russell Hilf@urmc.rochester.edu
Havens
J J
JJ
Gibson
S L
SL
D000622:Aminolevulinic Acid / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000378:metabolism*; D004247:DNA / Q000187:drug effects* / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D011163:Hydroxymethylbilane Synthase / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism*; D008654:Mesothelioma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000378:metabolism; D010778:Photochemotherapy; D010957:Plasmids / Q000187:drug effects / Q000235:genetics; D011524:Protoporphyrins / Q000378:metabolism*; D014162:Transfection; D014407:Tumor Cells, Cultured
D011524:Protoporphyrins; D000622:Aminolevulinic Acid; D004247:DNA; C028025:protoporphyrin IX; D011163:Hydroxymethylbilane Synthase